{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:04:56Z","timestamp":1780563896246,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06489-9","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:34:48Z","timestamp":1780562088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early vs. delayed primary local therapy and survival in de novo metastatic prostate cancer: target trial emulation"],"prefix":"10.1007","volume":"44","author":[{"given":"Atef A.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Y.","family":"Aboelsaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M. Abdel","family":"Gawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M.","family":"El-Dydamony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed I.","family":"Algammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Abdel-Al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman K.","family":"Koritenah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek M.","family":"Abuelazayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed F.","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed F.","family":"El-Wahsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam A.","family":"Shouman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Hindawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Deif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Samir","family":"Wasfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"1","key":"6489_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6489_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6489_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","volume":"4","author":"SP Kelly","year":"2018","unstructured":"Kelly SP, Anderson WF, Rosenberg PS, Cook MB (2018) Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. Eur Urol Focus 4(1):121\u2013127","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6489_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001375","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R et al (2021) Advanced Prostate Cancer: AUA\/ASTRO\/SUO Guideline PART I. J Urol 205(1):14\u201321","journal-title":"J Urol"},{"issue":"1","key":"6489_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jnci\/djaa068","volume":"113","author":"A Jemal","year":"2021","unstructured":"Jemal A, Culp MB, Ma J, Islami F, Fedewa SA (2021) Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening. JNCI J Natl Cancer Inst 113(1):64\u201371","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"5","key":"6489_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","volume":"3","author":"JC Hu","year":"2017","unstructured":"Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD et al (2017) Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. JAMA Oncol 3(5):705","journal-title":"JAMA Oncol"},{"key":"6489_CR7","doi-asserted-by":"crossref","unstructured":"Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK et al (2018) Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. July;124(13):2801\u201314","DOI":"10.1002\/cncr.31549"},{"issue":"1","key":"6489_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","volume":"169","author":"TR Glass","year":"2003","unstructured":"Glass TR, Tangen CM, Crawford ED, Thompson I (2003) Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning. J Urol 169(1):164\u2013169","journal-title":"J Urol"},{"issue":"8","key":"6489_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"10024","key":"6489_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u20131177","journal-title":"Lancet"},{"key":"6489_CR11","doi-asserted-by":"crossref","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017 July 27;377(4):352\u2013360","DOI":"10.1056\/NEJMoa1704174"},{"key":"6489_CR12","doi-asserted-by":"crossref","unstructured":"James ND, De Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017 July 27;377(4):338\u2013351","DOI":"10.1056\/NEJMoa1702900"},{"key":"6489_CR13","doi-asserted-by":"crossref","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with Standard first-line therapy in metastatic prostate cancer. N Engl J Med. July 11;381(2):121\u201331","DOI":"10.1056\/NEJMoa1903835"},{"issue":"32","key":"6489_CR14","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"key":"6489_CR15","doi-asserted-by":"crossref","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira De Santana Gomes AJ, Given R et al (2019 July) Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 4(1):13\u201324","DOI":"10.1056\/NEJMoa1903307"},{"issue":"3421","key":"6489_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S, The distribution of secondary, growths in cancer of the breast (1889) Lancet 133(3421):571\u2013573","journal-title":"Lancet"},{"issue":"1","key":"6489_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR, Oligometastases (1995) J Clin Oncol 13(1):8\u201310","journal-title":"J Clin Oncol"},{"key":"6489_CR18","doi-asserted-by":"crossref","unstructured":"Culp SH, Schellhammer PF, Williams MB (2014 June) Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. Eur Urol 65(6):1058\u20131066","DOI":"10.1016\/j.eururo.2013.11.012"},{"issue":"6","key":"6489_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pros.23294","volume":"77","author":"RR Parikh","year":"2017","unstructured":"Parikh RR, Byun J, Goyal S, Kim IY (2017) Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer: Local Therapy for Metastatic Prostate Cancer. Prostate 77(6):559\u2013572","journal-title":"Prostate"},{"key":"6489_CR20","doi-asserted-by":"crossref","unstructured":"L\u00f6ppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP et al (2017 July) The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. Eur Urol 72(1):14\u201319","DOI":"10.1016\/j.eururo.2016.04.031"},{"issue":"10162","key":"6489_CR21","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"issue":"3","key":"6489_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ et al (2019) Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 75(3):410\u2013418","journal-title":"Eur Urol"},{"issue":"2","key":"6489_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, Van Den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 79(2):263\u2013282","journal-title":"Eur Urol"},{"issue":"3","key":"6489_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B et al (2024) NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024. J Natl Compr Cancer Netw JNCCN 22(3):140\u2013150","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"14","key":"6489_CR25","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K et al (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol 34(14):1652\u20131659","journal-title":"J Clin Oncol"},{"issue":"2","key":"6489_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V et al (2015) Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68(2):325\u2013334","journal-title":"Eur Urol"},{"issue":"1","key":"6489_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","volume":"65","author":"GR Pond","year":"2014","unstructured":"Pond GR, Sonpavde G, De Wit R, Eisenberger MA, Tannock IF, Armstrong AJ (2014) The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 65(1):3\u20136","journal-title":"Eur Urol"},{"key":"6489_CR28","doi-asserted-by":"crossref","unstructured":"Lai GS, Chen CS, Cheng JCH, Li JR, Yang CK, Lin CY et al (2024) Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. Bauckneht M, editor. PLOS ONE. Sept 6;19(9):e0309941","DOI":"10.1371\/journal.pone.0309941"},{"issue":"mar12 1","key":"6489_CR29","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE Levesque","year":"2010","unstructured":"Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340(mar12 1):b5087\u2013b5087","journal-title":"BMJ"},{"issue":"8","key":"6489_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. Am J Epidemiol 183(8):758\u2013764","journal-title":"Am J Epidemiol"},{"issue":"24","key":"6489_CR31","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE (2022) Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA 328(24):2446","journal-title":"JAMA"},{"issue":"5","key":"6489_CR32","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","volume":"49","author":"C Maringe","year":"2020","unstructured":"Maringe C, Benitez Majano S, Exarchakou A, Smith M, Rachet B, Belot A et al (2020) Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int J Epidemiol 49(5):1719\u20131729","journal-title":"Int J Epidemiol"},{"issue":"12","key":"6489_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","volume":"334","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, Hansford HJ, Hern\u00e1n MA, Swanson SA, Lee H, Jones MD et al (2025) Transparent reporting of observational studies emulating a target trial\u2014the TARGET statement. JAMA 334(12):1084\u20131093","journal-title":"JAMA"},{"key":"6489_CR34","doi-asserted-by":"crossref","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL et al (2019 July) Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur Urol 76(1):115\u2013124","DOI":"10.1016\/j.eururo.2019.02.003"},{"issue":"10336","key":"6489_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399(10336):1695\u20131707","journal-title":"Lancet"},{"key":"6489_CR36","doi-asserted-by":"crossref","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, McDermott RS, Flechon A et al (2023) Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. J Clin Oncol. June 10;41(17_suppl):LBA5000\u2013LBA5000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5000"},{"issue":"2","key":"6489_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","volume":"194","author":"R Satkunasivam","year":"2015","unstructured":"Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L et al (2015) Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol 194(2):378\u2013385","journal-title":"J Urol"},{"issue":"2","key":"6489_CR38","first-page":"80","volume":"7","author":"CF Polotti","year":"2019","unstructured":"Polotti CF, Sterling JA, Kim IY (2019) Cytoreductive prostatectomy in metastatic prostate cancer: current knowledge and future directions. Am J Clin Exp Urol 7(2):80\u201384","journal-title":"Am J Clin Exp Urol"},{"issue":"11","key":"6489_CR39","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"},{"issue":"8","key":"6489_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00066-022-01961-y","volume":"198","author":"AC M\u00fcller","year":"2022","unstructured":"M\u00fcller AC, Aebersold DM, Albrecht C, B\u00f6hmer D, Flentje M, Ganswindt U et al (2022) Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al 198(8):683\u2013689","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"issue":"3","key":"6489_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","volume":"193","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A, Pfister D, Porres D (2015) Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study. J Urol 193(3):832\u2013838","journal-title":"J Urol"},{"issue":"5","key":"6489_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 36(5):446\u2013453","journal-title":"J Clin Oncol"},{"key":"6489_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I (2016) Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70\u201375","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"6489_CR44","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","volume":"34","author":"EL Fu","year":"2023","unstructured":"Fu EL (2023) Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How? J Am Soc Nephrol 34(8):1305\u20131314","journal-title":"J Am Soc Nephrol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06489-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:34:59Z","timestamp":1780562099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06489-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6489"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06489-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve direct interaction with human subjects, as it relied on publicly available de-identified data from the SEER database. Therefore, institutional ethics approval and informed consent were not required. The study complies with all relevant ethical regulations and guidelines for research using secondary data sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"During the preparation of this work, the authors used Gemini 3 Pro to assist with language polishing and organisation. After using this tool, the authors reviewed and edited the content and took full responsibility for the article. No generative AI or AI-assisted tools were used to create or modify figures, images, or artwork.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative-AI use declaration"}}],"article-number":"409"}}